Boehringer launches 81% discounted biosimilar of AbbVie’s Humira

[ad_1] The logo of German pharmaceutical company Boehringer Ingelheim is seen at its building in Shanghai, China February 1, 2019. REUTERS/Stringer/File Photo Acquire Licensing Rights Oct 2 (Reuters) – Germany’s…

The End of AbbVie’s $200 Billion Monopoly Won’t Sink the Stock

[ad_1] The drugmaker is offering steep discounts on its immune-disease therapy Humira to protect market share this year. [ad_2] Source link